secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2026-08-06T20:08:20+00:00
Accession:  0001193125-26-337974
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi Therapeutics Q2 2026 net loss $17.8M; cash $318.9M; Phase 3 OCEAN-1 initiated
--------------------------------------------------------------------------------

- Net loss of $17.8M in Q2 2026 vs $12.3M in Q2 2025; R&D expenses $15.2M (up from $9.4M).
- Cash, cash equivalents and marketable securities $318.9M; April 2026 stock offering netted $162.3M; cash runway into 2030.
- Initiated Phase 3 OCEAN-1 trial for IPF-related chronic cough; topline data expected H1 2028.
- Initiated Phase 2b LAKE trial for refractory chronic cough; sample size re-estimation expected Q4 2026.
- Submitted FDA meeting request for non-IPF ILD-related chronic cough development plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000119312526337974/0001193125-26-337974-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000119312526337974/trvi-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-337974

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer